Scott T. Tagawa, MD

Articles

Dr. Tagawa on Tumor Targeting With Radionuclides in Prostate Cancer

July 8th 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

Dr. Tagawa on the FDA Approval of Sacituzumab Govitecan in Advanced Urothelial Carcinoma

April 14th 2021

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

Dr. Tagawa on Significance of BRCA2 With PSMA-Targeted Radionuclide Therapy in Prostate Cancer

July 17th 2019

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

June 17th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

Dr. Tagawa Discusses Darolutamide in CRPC

March 28th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Dr. Tagawa on Sacituzumab Govitecan in Urothelial Carcinoma

February 15th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.

Dr. Tagawa Discusses Radiotherapy in Prostate Cancer

November 8th 2018

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Dr. Tagawa on Next Steps for Taxanes in Prostate Cancer

March 2nd 2017

Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.

Dr. Tagawa on Updated Results of TAXYNERGY Trial in Prostate Cancer

February 23rd 2017

Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Tagawa on IMMU-132 Trial Updates in Urothelial Cancer

February 16th 2017

Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

May 31st 2016

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Dr. Tagawa on CTCs in Neuroendocrine Prostate Cancer

April 11th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.

Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC

January 30th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.